Clinical Efficacy Evaluation of Sirolimus in Congenital Hyperinsulinism
Background. Congenital hyperinsulinism (CHI) is a rare and life-threatening genetic disorder. Sirolimus as a mammalian target of rapamycin inhibitor may be helpful in patients with CHI who do not respond well to other treatments including diazoxide and octreotide. However, the safety and efficacy of...
Saved in:
Main Authors: | Somayyeh Hashemian, Reza Jafarzadeh Esfehani, Siroos Karimdadi, Rahim Vakili, Daniel Zamanfar, Amirhossein Sahebkar |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2020/7250406 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First Report of Diabetes Phenotype due to a Loss-of-Function ABCC8 Mutation Previously Known to Cause Congenital Hyperinsulinism
by: Theocharis Koufakis, et al.
Published: (2019-01-01) -
Dramatic Response to Sirolimus in Lymphangioleiomyomatosis
by: Dmitry Rozenberg, et al.
Published: (2013-01-01) -
Arterial Calcium Stimulation with Hepatic Venous Sampling in the Localization Diagnosis of Endogenous Hyperinsulinism
by: Paloma Moreno-Moreno, et al.
Published: (2016-01-01) -
Sirolimus for the Treatment of Airway Obstruction due to Indolent T-Lymphoblastic Proliferation
by: Eric Moughames, et al.
Published: (2019-01-01) -
Percutaneous Coronary Intervention Using the DynamX Sirolimus-Eluting Bioadaptor: 12-Month Clinical and Imaging Outcomes
by: Mark Webster, et al.
Published: (2024-01-01)